DiaMedica Therapeutics Inc [NASDAQ: DMAC] gained 0.71% on the last trading session, reaching $5.71 price per share at the time.
If compared to the average trading volume of 94.31K shares, DMAC reached a trading volume of 249075 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about DiaMedica Therapeutics Inc [DMAC]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DMAC shares is $8.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DMAC stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for DiaMedica Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 07, 2024. While these analysts kept the previous recommendation, Craig Hallum raised their target price to Buy. The new note on the price target was released on April 24, 2024, representing the official price target for DiaMedica Therapeutics Inc stock. Previously, the target price had yet another raise to $7, while Oppenheimer analysts kept a Outperform rating on DMAC stock.
The Average True Range (ATR) for DiaMedica Therapeutics Inc is set at 0.43 The Price to Book ratio for the last quarter was 5.09, with the Price to Cash per share for the same quarter was set at 1.17.
Trading performance analysis for DMAC stock
DiaMedica Therapeutics Inc [DMAC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 8.35. With this latest performance, DMAC shares gained by 7.53% in over the last four-week period, additionally plugging by 75.15% over the last 6 months – not to mention a rise of 106.88% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DMAC stock in for the last two-week period is set at 56.89, with the RSI for the last a single of trading hit 59.11, and the three-weeks RSI is set at 56.27 for DiaMedica Therapeutics Inc [DMAC]. The present Moving Average for the last 50 days of trading for this stock 5.04, while it was recorded at 5.35 for the last single week of trading, and 3.83 for the last 200 days.
DiaMedica Therapeutics Inc [DMAC]: A deeper dive into fundamental analysis
DiaMedica Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.81 and a Current Ratio set at 11.81.
An analysis of Institutional ownership at DiaMedica Therapeutics Inc [DMAC]
There are presently around $31.61%, or 42.84%% of DMAC stock, in the hands of institutional investors. The top three institutional holders of DMAC stocks are: COOPERMAN LEON G with ownership of 1.4 million shares, which is approximately 3.6883%. VANGUARD GROUP INC, holding 1.02 million shares of the stock with an approximate value of $$3.0 million in DMAC stocks shares; and VANGUARD GROUP INC, currently with $$2.48 million in DMAC stock with ownership which is approximately 2.2106%.
